Loading
Intravenous acetazolamide 500 mg OD / Acute Heart Failure / Oral chlorthalidone OD · Phase 4 Trial
ClinicalTrials.gov · September 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a completed Phase 4 pragmatic randomized trial comparing urine sodium-guided diuretic therapy to usual care in acute heart failure with volume overload. No trial results are posted in this registry record; the study design, interventions, and primary endpoints (mortality, hospital days, decongestion at 30 days) are documented but outcomes remain unreported.
Phase 4, Interventional, Randomized, Parallel, Open label, Treatment purpose. Acute Heart Failure, Diuretics Drug Reactions; age from 18 Years; to 99 Years. Intervention: Intervention arm. Compared with: Control arm — Active Comparator. n = 107. 2 sites: Belgium.
This is a completed Phase 4 pragmatic randomized trial comparing urine sodium-guided diuretic therapy to usual care in acute heart failure with volume overload. No trial results are posted in this registry record; the study design, interventions, and primary endpoints (mortality, hospital days, decongestion at 30 days) are documented but outcomes remain unreported.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
If results support the urine sodium-guided strategy, this pragmatic trial could inform decongestion protocols in acute heart failure. However, clinicians must await published results; no efficacy or safety data are available from this registry record.
Phase 4 interventional trial with enrollment completed but no results posted in registry; study design and planned endpoints are stated but outcomes remain unreported.
As stated by the source record.
Quoted from the source exactly as published.
If results support the urine sodium-guided strategy, this pragmatic trial could inform decongestion protocols in acute heart failure. However, clinicians must await published results; no efficacy or safety data are available from this registry record.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05411991). This is a study registration, not published results. Lead sponsor: Vrije Universiteit Brussel. Recruitment status: COMPLETED. Phase: PHASE4. Study type: INTERVENTIONAL. Enrollment: 107 participants (ACTUAL). Conditions: Acute Heart Failure, Diuretics Drug Reactions. Interventions: DIAGNOSTIC_TEST: UNa measurement after intravenous loop diuretic bolus; DRUG: Intravenous acetazolamide 500 mg OD; DRUG: Intravenous bumetanide TID; DRUG: Oral chlorthalidone OD; DRUG: Intravenous canrenoate 200 mg OD; OTHER: Maintenance infusion; DRUG: Oral potassium supplements; OTHER: Intravenous hypertonic saline; OTHER: Switch to oral diuretic therapy; OTHER: Usual AHF care. Primary outcome measures: Mortality, Days in Hospital & Decongestion , 30 days. Brief summary: This is a pragmatic, multicenter, interventional, parallel-arm, randomized, open-label trial to investigate whether a diuretic regimen, based on serial assessment of sodium concentration (UNa) on spot urine samples after diuretic administration and with low-threshold use of combination diuretic therapy, improves decongestion versus usual care in acute heart failure (AHF), potentially leading to better clinical outcomes.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.